Related Experiment Video
Updated: Jul 20, 2026
13:38
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
[Aspirin resistance theory].
Aleksandra Porosińska1, Krystyna Pierzchała
1Katedra i Klinika Neurologii, Slaska Akademia Medyczna, ul. 3 Maja 13/15, 41-800 Zabrze. aleksandraporosinska@tlen.pl
Neurologia I Neurochirurgia Polska
|September 13, 2006
Summary
Acetylsalicylic acid effectively prevents vascular events in atherosclerosis patients. However, increasing reports of aspirin resistance are a growing concern for cardiovascular and cerebrovascular disease prevention.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Neurology
Context:
- Acetylsalicylic acid (aspirin) is a widely used antiplatelet medication.
- It plays a crucial role in preventing heart and brain vascular diseases, including atherosclerosis.
- Clinical trials demonstrate significant reductions in ischemic events and vascular death with aspirin use.
Purpose:
- To review current understanding and research findings on aspirin resistance.
- To highlight the clinical implications of aspirin's reduced efficacy in certain patients.
- To consolidate expert opinions on managing aspirin resistance.
Summary:
- Aspirin effectively reduces vascular ischemic events by 25% and vascular death risk in atherosclerosis patients.
- A concerning rise in reports of aspirin resistance, where the drug fails to prevent ischemic events, has been observed.
- This review examines the current scientific landscape surrounding aspirin resistance.
Impact:
- Addresses a critical clinical challenge in cardiovascular and cerebrovascular disease management.
- Provides insights for healthcare professionals regarding treatment efficacy and patient monitoring.
- Informs future research directions for optimizing antiplatelet therapy and overcoming resistance mechanisms.
More Related Videos
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:25Mechanism of Antibiotic Resistance in MRSA
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:30Development of Antibiotic Resistance
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
01:20Desensitization and Tachyphylaxis
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Several...